Top Industry Leaders in the Conjunctivitis Drugs Market
Latest Conjunctivitis Drugs Companies Update
Allergan Received FDA approval for Rexulti® (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.
Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.
Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.
Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.
EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.
List of Conjunctivitis Drugs Key Companies in the Market
- Akorn Pharmaceuticals (US)
- Alcon/Novartis AG (Switzerland)
- Allergan Plc (Ireland)
- Bausch and Lomb (US)
- Actavis Plc (US)
- Pfizer Inc (US)
- Merck and Co. Inc. (US)
- Lupin Limited (India)
- Valeant Pharmaceuticals (Canada)